COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era

dc.contributor.authorDeyá Martínez, Àngela
dc.contributor.authorGarcía García, Ana Pilar
dc.contributor.authorGonzález Navarro, E. Azucena
dc.contributor.authorYiyi, Luo
dc.contributor.authorVlagea, Alexandru
dc.contributor.authorJordán García, Iolanda
dc.contributor.authorFumadó, Victoria
dc.contributor.authorFortuny, Clàudia
dc.contributor.authorEspañol Rego, Marta
dc.contributor.authorLaunes Montaña, Cristian
dc.contributor.authorEsteve-Solé, Ana
dc.contributor.authorJuan, Manel
dc.contributor.authorPascal i Capdevila, Mariona
dc.contributor.authorAlsina Manrique de Lara, Laia
dc.date.accessioned2026-06-22T14:33:52Z
dc.date.available2026-06-22T14:33:52Z
dc.date.issued2021-08-12
dc.date.updated2026-06-22T14:33:52Z
dc.description.abstractBackground Information regarding inborn error of immunity (IEI) as a risk factor for severe COVID-19 is scarce. We aimed to determine if paediatric patients with moderate/severe IEI got COVID-19 at the same level as the general population, and to describe COVID-19 expression. Material and methods We included patients with moderate/severe IEI aged 0–21 years old: cross-sectional study (June2020) to determine the prevalence of COVID-19; prospective study (January2020-January2021) including IEI patients with COVID-19. Assays used: nasopharyngeal swab SARS-CoV-2 PCR and SARS-CoV-2-specific immunoglobulins. Results Seven from sixty-five patients tested positive (prevalence: 10.7% (7%–13%)) after the first SARS-COV-2 wave and 13/15 patients diagnosed with COVID-19 had an asymptomatic/mild course. Conclusions In our area, prevalence of COVID-19 in moderate/severe IEI paediatric patients after the first wave was slightly higher than in the general population. The majority of patients presented a benign course, suggesting a possible protective factor related with age despite IEI.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec731351
dc.identifier.issn1521-6616
dc.identifier.pmid34391937
dc.identifier.urihttps://hdl.handle.net/2445/230151
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.clim.2021.108821
dc.relation.ispartofClinical Immunology, 2021
dc.relation.urihttps://doi.org/10.1016/j.clim.2021.108821
dc.rightscc-by (c) Deyá Martínez, Àngela et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationCOVID-19
dc.subject.classificationVacunació dels infants
dc.subject.otherCOVID-19
dc.subject.otherVaccination of children
dc.titleCOVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
258350.pdf
Mida:
1.07 MB
Format:
Adobe Portable Document Format